Equities Analysts Set Expectations for PMN Q2 Earnings

Promis Neurosciences (NASDAQ:PMN) – Equities research analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Promis Neurosciences in a note issued to investors on Monday, June 8th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.01) per share for the quarter, up from their previous estimate of ($1.54). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. HC Wainwright also issued estimates for Promis Neurosciences’ Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($4.57) EPS, Q1 2027 earnings at ($1.14) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.86) EPS and FY2027 earnings at ($3.33) EPS.

Other research analysts have also issued research reports about the company. Brookline Capital Markets raised Promis Neurosciences to a “strong-buy” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Promis Neurosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.50.

Promis Neurosciences Price Performance

Shares of PMN opened at $9.74 on Wednesday. The company has a 50-day simple moving average of $11.03 and a two-hundred day simple moving average of $12.03. The firm has a market capitalization of $87.37 million, a PE ratio of -0.67 and a beta of -0.19. Promis Neurosciences has a one year low of $6.27 and a one year high of $39.75.

Promis Neurosciences (NASDAQ:PMN) last announced its earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20).

Institutional Trading of Promis Neurosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Ally Bridge Group NY LLC raised its holdings in Promis Neurosciences by 367.1% in the third quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock worth $2,649,000 after buying an additional 4,899,069 shares during the last quarter. Citadel Advisors LLC grew its holdings in shares of Promis Neurosciences by 168.1% during the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock valued at $72,000 after buying an additional 106,650 shares during the last quarter. Armistice Capital LLC increased its position in shares of Promis Neurosciences by 39.1% during the third quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock valued at $1,264,000 after acquiring an additional 836,622 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Promis Neurosciences during the first quarter valued at approximately $1,211,000. Finally, Yu Fan purchased a new position in Promis Neurosciences in the 1st quarter worth approximately $4,188,000. 50.13% of the stock is currently owned by institutional investors.

Insider Activity at Promis Neurosciences

In related news, Director Patrick D. Kirwin purchased 4,000 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was purchased at an average price of $11.33 per share, with a total value of $45,320.00. Following the transaction, the director directly owned 4,653 shares in the company, valued at $52,718.49. This trade represents a 612.56% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Promis Neurosciences Company Profile

Promis Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small?molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.